PMID- 23991635 OWN - NLM STAT- MEDLINE DCOM- 20140627 LR - 20220410 IS - 1469-0691 (Electronic) IS - 1198-743X (Linking) VI - 19 IP - 12 DP - 2013 Dec TI - Cost-benefit of infection control interventions targeting methicillin-resistant Staphylococcus aureus in hospitals: systematic review. PG - E582-93 LID - 10.1111/1469-0691.12280 [doi] AB - Infections caused by methicillin-resistant Staphylococcus aureus (MRSA) incur significant costs. We aimed to examine the cost and cost-benefit of infection control interventions against MRSA and to examine factors affecting economic estimates. We performed a systematic review of studies assessing infection control interventions aimed at preventing spread of MRSA in hospitals and reporting intervention costs, savings, cost-benefit or cost-effectiveness. We searched PubMed and references of included studies with no language restrictions up to January 2012. We used the Quality of Health Economic Studies tool to assess study quality. We report cost and savings per month in 2011 US$. We calculated the median save/cost ratio and the save-cost difference with interquartile range (IQR) range. We examined the effects of MRSA endemicity, intervention duration and hospital size on results. Thirty-six studies published between 1987 and 2011 fulfilled inclusion criteria. Fifteen of the 18 studies reporting both costs and savings reported a save/cost ratio >1. The median save/cost ratio across all 18 studies was 7.16 (IQR 1.37-16). The median cost across all studies reporting intervention costs (n = 31) was 8648 (IQR 2025-19 170) US$ per month; median savings were 38 751 (IQR 14 206-75 842) US$ per month (23 studies). Higher save/cost ratios were observed in the intermediate to high endemicity setting compared with the low endemicity setting, in hospitals with <500-beds and with interventions of >6 months. Infection control intervention to reduce spread of MRSA in acute-care hospitals showed a favourable cost/benefit ratio. This was true also for high MRSA endemicity settings. Unresolved economic issues include rapid screening using molecular techniques and universal versus targeted screening. CI - (c) 2013 The Authors Clinical Microbiology and Infection (c) 2013 European Society of Clinical Microbiology and Infectious Diseases. FAU - Farbman, L AU - Farbman L AD - Medicine E, Rabin Medical Centre, Beilinson Hospital, Petah-Tikva, Israel; Leon Recanati Faculty of Management and Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel. FAU - Avni, T AU - Avni T FAU - Rubinovitch, B AU - Rubinovitch B FAU - Leibovici, L AU - Leibovici L FAU - Paul, M AU - Paul M LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review PT - Systematic Review DEP - 20130828 PL - England TA - Clin Microbiol Infect JT - Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases JID - 9516420 SB - IM MH - Cost Savings MH - Cost-Benefit Analysis MH - Cross Infection/epidemiology/microbiology/*prevention & control/transmission MH - Hospitals MH - Humans MH - Infection Control/*economics/methods MH - *Methicillin-Resistant Staphylococcus aureus MH - Staphylococcal Infections/epidemiology/microbiology/*prevention & control/transmission OTO - NOTNLM OT - Contact isolation OT - MRSA OT - cost-benefit OT - decolonization OT - economic analysis OT - screening EDAT- 2013/09/03 06:00 MHDA- 2014/06/28 06:00 CRDT- 2013/09/03 06:00 PHST- 2013/02/12 00:00 [received] PHST- 2013/05/12 00:00 [revised] PHST- 2013/05/23 00:00 [accepted] PHST- 2013/09/03 06:00 [entrez] PHST- 2013/09/03 06:00 [pubmed] PHST- 2014/06/28 06:00 [medline] AID - S1198-743X(14)63098-6 [pii] AID - 10.1111/1469-0691.12280 [doi] PST - ppublish SO - Clin Microbiol Infect. 2013 Dec;19(12):E582-93. doi: 10.1111/1469-0691.12280. Epub 2013 Aug 28.